Biomarker-Associated Remission with Anti-IL-4R/IL-13 Therapy After Failure of Prior Biologics in Severe Asthma
Authors:
- Fabio Romano SelviFSFabio Romano Selvi
- David LonghinoDLDavid Longhino
- Gabriele LuccaGLGabriele Lucca
- Ilaria BaglivoIBIlaria Baglivo
- Maria Antonietta ZavarellaMZMaria Antonietta Zavarella
- Chiara LafaceCLChiara Laface
- Laura BrunoLBLaura Bruno
- Arianna Delfino SpigaASArianna Delfino Spiga
- Sara GamberaleSGSara Gamberale
- Ludovica FabbroniLFLudovica Fabbroni
- Angela RizziAngela Rizzi
- Arianna AruannoAAArianna Aruanno
Preprint
- 11 August 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives Severe asthma remains difficult to treat, even with the range of biologics we now have that target type 2 inflammation. Some patients do not respond well enough to the first biologic they try, which raises the question of whether switching to another option can help. In this study, we looked at how patients who had unsatisfactory therapeutic outcomes on other biologics responded—both clinically and at the biomarker level—after switching to dupilumab. Methods We reviewed data from the Allergy and Clinical Immunology Unit of Fondazione Policlinico Universitario A. Gemelli-IRCCS between January and June 2025. The study included fifteen adults with uncontrolled severe asthma who had previously been treated for at least six months with benralizumab, omalizumab, or mepolizumab before switching to dupilumab. We assessed lung function (FEV₁), blood eosinophils, IgE, eosinophil cationic protein (ECP), free light chains (FLC), and FeNO at the time of the switch and again after 12 months. Statistical comparisons were made using paired tests, with significance set at p < 0.05. Results After a year on dupilumab, we saw clear improvements: mean FEV₁ went up by about 10.8% predicted (p = 0.002), FeNO dropped by an average of 22 ppb (p = 0.005), blood eosinophils fell by roughly 400 cells/µL (p = 0.003), and ECP levels decreased by 13 µg/L (p = 0.009). Kappa FLCs also showed a significant drop (p = 0.04). Clinically, 40% of patients met criteria for a meaningful response, and 20% achieved complete remission. Dependence on oral corticosteroids was notably reduced. Baseline levels of eosinophils, ECP, IgE, and FLCs correlated with response to treatment. Conclusions For patients with severe asthma who do not show a good response to their first biologic, switching to dupilumab can lead to significant clinical and biomarker improvements. Markers of type 2 inflammation at baseline might help predict who benefits most. Larger, prospective studies are needed to confirm these results.Keywords
All Related Versions
- Version 1, 2025-08-11, Preprints
- Published version: Biomedicines, 13 (9), 2096.
This publication has 22 references indexed in Scilit:
- Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort studyRespiratory Medicine, 2024
- Complications of switching from anti–IL-5 or anti–IL-5R to dupilumab in corticosteroid-dependent severe asthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody TherapyThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- EAACI Biologicals Guidelines—Recommendations for severe asthmaAllergy, 2020
- The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthmaAllergy, 2019
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatmentAllergy, 2016
- Acute and chronic systemic corticosteroid–related complications in patients with severe asthmaJournal of Allergy and Clinical Immunology, 2015
- Type 2 inflammation in asthma — present in most, absent in manyNature Reviews Immunology, 2014